Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML)

Myelodysplastic Syndrome Clinical Trial

Official title:

A Phase 2, Multicenter, Open-label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Activity of Azacitidine and to Compare Azacitidine to Historical Controls in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome or Juvenile Myelomonocytic Leukemia Before Hematopoietic Stem Cell Transplantation

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02447666
• Other study ID #: AZA-JMML-001
• Status: Completed
• Phase: Phase 2
• Start date: September 15, 2015
• Est. completion date: May 24, 2019

Study information

• Verified date: July 2019
• Source: Celgene
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Indication Treatment of pediatric subjects with newly diagnosed advanced myelodysplastic syndrome (MDS) or juvenile myelomonocytic leukemia (JMML) prior to hematopoietic stem cell transplantation (HSCT).

Objectives Primary Objective The primary objective is to assess the treatment effect on response rate (MDS: either complete remission [CR], partial remission [PR], or marrow CR; JMML: either clinical complete remission [cCR] or clinical partial remission [cPR]); at Cycle 3 Day 28 (each cycle is 28 days) and to compare against standard therapy using a matched-pairs analysis of historical data.

Secondary Objective The secondary objective is to further evaluate safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of azacitidine in this subject population.

Study Design This is a prospective, open-label, Phase 2 study consisting of 2 parallel experimental arms, one for each disease group: MDS and JMML. Each arm is designed based on Simon's Optimal 2 stage study design. The sample size has been calculated to allow evaluation of the response rate at 28 day-Cycle 3 Day 28 in each of the 2 disease groups. Each of the experimental arms will also individually be compared against a historical control arm using data retrospectively collected from the European Working Group of MDS in childhood (EWOG-MDS) registry by means of a matched-pairs analysis; matched for predefined subject baseline characteristics defined before any results from this study are known post Stage 1. If matched pair is not viable then other methodologies will be explored to evaluate and compare response rates reported in literature and also in registry database Twenty subjects with MDS and 35 JMML subjects evaluable for the primary endpoint (ie, subjects that receive at least 1 dose of investigational product [IP]) will be enrolled at approximately 45 centers in Europe. Each experimental arm has 1 interim analysis planned (at the end of Stage 1). If, during Stage 1 evaluation, less than 2 subjects are observed with a CR, PR, or marrow CR after 3 months of azacitidine in the first 9 subjects with MDS, then enrollment will be stopped. Similarly, if less than 3 subjects are observed with a cPR or cCR after 3 months of azacitidine in the first 18 subjects with JMML, then enrollment will be stopped.

Description:

Study Population Pediatric subjects aged 1 month to less than 18 years of age with newly diagnosed conditions of advanced myelodysplastic syndrome (MDS) or juvenile myelomonocytic leukemia (JMML).

Length of Study The enrollment period will last for up to 22 months with subjects being treated for a minimum of 3 months and a maximum of 6 months, until transplantation or disease progression (based on an independent central review of responses). Once investigational product (IP) has been discontinued, subjects will then be followed for 1 year after the last dose of investigational product (IP). The follow-up may not be terminated because of new anticancer treatment or hematopoietic stem cell transplantation (HSCT).

The End of Trial is defined as either the date of the last visit of the last subject to complete the study, or the date of receipt of the last data point from the last subject that is required for primary, secondary and/or exploratory analysis, as pre-specified in the protocol and/or the Statistical Analysis Plan (SAP), whichever is the later date.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 28
• Est. completion date: May 24, 2019
• Est. primary completion date: February 28, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 1 Month to 18 Years

Eligibility

Inclusion Criteria:

Myelodysplastic Syndromes (MDS) :

1. Understand and voluntarily provide permission (subjects and/or when applicable, parental/legal representative) to the informed consent form/informed assent form (ICF/IAF) prior to conducting any study-related assessments/procedures.

2. Able to adhere to the study visit schedule and other protocol requirements.

3. Male or female age 1 month to less than 18 years old at the time of informed consent/informed assent.

4. Newly diagnosed advanced primary or secondary Myelodysplastic Syndromes (MDS), with latest peripheral blood (PB) and bone marrow (BM) biopsy confirming diagnosis within the 14 days prior to informed consent signature, with one of the following:

1. RAEB (Refractory anemia with excess blasts): 2% to 19% blasts in PB or 5% to 19% blasts in BM.

2. RAEB-t (Refractory anemia with excess blasts in transformation): 20% to 29% of blasts in PB or BM.

3. Secondary Myelodysplastic Syndromes presenting as chronic myelomonocytic leukemia (CMML) without increase in blasts but with chromosomal abnormality

5. Lansky play score at least equal to 60; or Karnofsky performance status at least equal to 60.

6. Life expectancy of at least 3 months.

7. Normal renal function defined as less than or equal to NCI CTCAE (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE]) v 4.0 Grade 1 (maximum 1.5 x Upper Limit of Normal [ULN]).

8. Normal liver function defined as less than or equal to NCI CTCAE v 4.0 Grade 1 (maximum 2.5 x ULN for transaminases and bilirubin).

9. Females of childbearing potential and male subjects that have reached puberty and are younger than 18 years of age must agree to undergo physician-approved reproductive education and discuss the side effects of the Investigational Product (IP) on reproduction with parent(s) and/or guardian(s).

10. Females of childbearing potential, defined as females who have achieved menarche and/or 8 years or older and have not undergone a hysterectomy or bilateral oophorectomy, must meet the following conditions below. (Note: Amenorrhea following cancer therapy does not rule out childbearing potential):

1. Have a negative serum pregnancy test within 72 hours prior to starting IP as verified by the Investigator. Agree to ongoing pregnancy testing during the course of the study

2. Female subjects must, as appropriate to age and the discretion of the study physician, either commit to true abstinence1 from heterosexual contact (which must be reviewed on a monthly basis) and/or agree to the use of approved contraceptive method (eg. oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; or vasectomized partner) while on azacitidine; and for 3 months following the last dose.

11. Male subjects must, as appropriate to age and the discretion of the study physician:

1. Agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential (FCBP) while participating in the study, during dose interruptions, and for at least 3 months following azacitidine discontinuation, even if he has undergone a successful vasectomy.

Juvenile Myelomonocytic Leukemia Subjects (JMML):

1. Understand and voluntarily provide permission (subjects and/or when applicable, parental/legal representative) to the ICF/IAF prior to conducting any study-related assessments/procedures.

2. Able to adhere to the study visit schedule and other protocol requirements.

3. Male or female age 1 month to less than 18 years old at the time of informed consent/informed assent.

4. Newly diagnosed Juvenile Myelomonocytic Leukemia (JMML), with PB and BM confirming diagnosis prior to informed consent signature, with one of the following

1. somatic mutation in PTPN11

2. somatic mutation in KRAS

3. somatic mutation in NRAS and HbF % > 5x normal value for age

4. clinical diagnosis of neurofibromatosis Type 1.

5. Lansky play score at least equal to 60; or Karnofsky performance status at least equal to 60.

6. Life expectancy of at least 3 months.

7. Normal renal function defined as less than or equal to NCI CTCAE v 4.0 Grade 1 (maximum 1.5 x ULN).

8. Normal liver function defined as less than or equal to NCI CTCAE v 4.0 Grade 1 (maximum 2.5 x ULN for transaminases and bilirubin).

9. Females of childbearing potential and male subjects that have reached puberty and are younger than 18 years of age must agree to undergo physician-approved reproductive education and discuss the side effects of the IP on reproduction with parent(s) and/or guardian(s).

10. Females of childbearing potential, defined as females who have achieved menarche and/or 8 years or older and have not undergone a hysterectomy or bilateral oophorectomy, must meet the following conditions below.

1. Have a negative serum pregnancy test within 72 hours prior to starting IP as verified by the Investigator. Agree to ongoing pregnancy testing during the course of the study

2. Female subjects must, as appropriate to age and the discretion of the study physician, either commit to true abstinence2 from heterosexual contact (which must be reviewed on a monthly basis) and/or agree to the use of approved contraceptive method (eg. oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; or vasectomized partner) while on azacitidine; and for 3 months following the last dose.

11. Male subjects must, as appropriate to age and the discretion of the study physician:

a. Agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential (FCBP) while participating in the study, during dose interruptions, and for at least 3 months following azacitidine discontinuation, even if he has undergone a successful vasectomy.

12. SO2 greater than 92% (without additional supply of O2).

13. Peripheral blood monocyte count of at least 1.0 x 109/L.

14. Blast percentage in PB and BM less than 20%.

15. Splenomegaly.

Exclusion Criteria:

Myelodysplastic Syndromes (MDS):

1. Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study.

2. Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study.

3. Any condition that confounds the ability to interpret data from the study.

4. Treated by any investigational agent in a clinical study within 4 weeks prior to signing of informed consent / informed assent.

5. Any central nervous system (CNS) involvement.

6. Isolated extramedullary disease.

7. Current uncontrolled infection.

8. Cardiac toxicity (shortening fraction below 28%).

9. Concurrent treatment with another anticancer therapy.

10. Pregnancy or lactation.

11. Prior treatment with a demethylating agent.

12. Allergy to azacitidine or mannitol.

13. Any other organ dysfunction (NCI-CTCAE v 4.0 Grade 4) that will interfere with the administration of the therapy according to this protocol.

14. Genetic abnormalities indicative of Core Binding factor AML; t(8;21), inv16, t(16;16), and t(15;17).

15. Subjects with inherited BM failure syndromes (ie, Fanconi's anemia, congenital severe neutropenia, Shwachman-Diamond syndrome).

Juvenile Myelomonocytic Leukemia Subjects:

1. Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study.

2. Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study.

3. Any condition that confounds the ability to interpret data from the study.

4. Treated by any investigational agent in a clinical study within 4 weeks prior to signing of informed consent / informed assent.

5. Any CNS involvement.

6. Isolated extramedullary disease.

7. Current uncontrolled infection.

8. Cardiac toxicity (shortening fraction below 28%).

9. Concurrent treatment with another anticancer therapy.

10. Pregnancy or lactation.

11. Prior treatment with a demethylating agent.

12. Allergy to azacitidine or mannitol.

13. Any other organ dysfunction (NCI-CTCAE v 4.0 Grade 4) that will interfere with the administration of the therapy according to this protocol.

14. Germline molecular aberrations in CBL, PTPN11, NRAS, or KRAS.

Related Conditions & MeSH terms

• Leukemia
• Leukemia, Myelomonocytic, Acute
• Leukemia, Myelomonocytic, Chronic
• Leukemia, Myelomonocytic, Juvenile
• Myelodysplastic Syndrome
• Myelodysplastic Syndromes
• Preleukemia
• Syndrome

Intervention

Drug:
• Azacitidine

Locations

Country	Name	City	State
Austria	St. Anna Kinderkrebsforschung, CHILDREN'S CANCER RESEARCH INSTITUTE	Vienna
Belgium	Hopital Universitaire des Enfants	Brussels
Belgium	University Hospital Ghent	Ghent
Czechia	University Hospital Motol	Prague 5
Denmark	Rigshospitalet	Copenhagen
France	Centre Hospitalier Universitaire Lyon	Lyon
France	Hopital d'Enfants de la Timone	Marseille Cedex 01
France	Hopital Robert Debre	Paris
Germany	Klinikum Augsburg	Augsburg
Germany	Charite Berlin	Berlin
Germany	Universitaetsklinikum Carl Gustav Carus	Dresden
Germany	Hematology, Oncology and clinical immunology / Heinrich-Heine-University	Dusseldorf
Germany	Universitatsklinikum Essen	Essen
Germany	Klinikum der Johann Wolfgang Goethe-Universität Frankfurt/Main	Frankfurt am Main
Germany	Universitatsklinik	Freiburg
Germany	University of Hamburg	Hamburg
Germany	Medizinische Hochschule Hannover	Hannover
Germany	Universitatsklinikum	Jena
Germany	Universitatsklinikum Schleswig-Holstein	Kiel
Germany	Klinikum der Universitaet Muenchen	Munchen
Germany	Universitatsklinik Munster	Münster
Germany	Krankenhaus Barmherzige Bruder Regensburg	Regensburg
Germany	Universitatsklinikum	Tübingen
Ireland	Our Lady's Hospital for Sick Children	Dublin 12
Italy	Policlinico Sant'Orsola-Malpighi	Bologna
Italy	IRCCS Gaslini Hospital	Genova Quarto
Italy	Azienda Ospedaliera San Gerardo	Monza
Italy	General Hospital	Padova
Italy	IRCCS Policlinico San Matteo	Pavia
Italy	Ospedale Bambin Gesu	Roma
Italy	Regina Margherita Children's Hospital	Torino
Netherlands	Erasmus University Medical Center	Rotterdam
Spain	Hospital Sant Joan de Deu	Barcelona
Spain	Hospital Infantil Universitario Nino Jesus	Madrid
Spain	Hospital Universitario Virgen de La Arrixaca	Murcia
Sweden	Queen Silvia Childrens Hospital	Gothenburg
Sweden	Karolinska University Hospital	Stockholm
Switzerland	Universitäts-Kinderklinik	Zurich
United Kingdom	Royal Manchester Children's Hospital	Manchester

Sponsors (1)

Lead Sponsor	Collaborator
Celgene

Countries where clinical trial is conducted

Austria,  Belgium,  Czechia,  Denmark,  France,  Germany,  Ireland,  Italy,  Netherlands,  Spain,  Sweden,  Switzerland,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Myelodysplastic Syndrome (MDS) response rate at end of third 28-day cycle	Defined as proportion of subjects with complete remission [CR], partial remission [PR] or marrow CR according to modified criteria described by Cheson 2006, adapted to pediatric reference values at 3 months (28 days cycle). Response must be sustained for at least 4 weeks either in the 4-week period preceding or succeeding 3 months (ie, sustained over the period minimum 2 months to end of 3 months, or end of 3 months to end of 4th months).	Up to 4 Months
Primary	Juvenile Myelomonocytic Leukemia (JMML) response rate at end of 3 Months	Defined as proportion of subjects with sustained clinical complete remission [cCR] or clinical partial remission [cPR] according to the International JMML response criteria in Niemeyer 2014 at 3 months (28 days cycles). Response must be sustained for at least 4 weeks either in the 4-week period preceding or succeeding 3 months (ie, sustained over the period minimum 2 months to end of 3 months, or end of 3 monthsto end of 4 months).	Up to 4 Months
Secondary	Cytogenetic response for MDS	Cytogenetic response is defined as the number of subjects with complete disappearance of the chromosomal abnormality without appearance of new ones divided by the number of subjects within the analysis population.	Up to 6 Months
Secondary	Cytogenetic response for JMML subjects	Cytogenetic response is defined as the number of subjects with complete disappearance of the chromosomal abnormality without appearance of new ones divided by the number of subjects within the analysis population.	Up to 6 Months
Secondary	Molecular Response for JMML subjects	Molecular response is defined as the number of subjects with absence of somatic mutations related to JMML divided by the number of subjects within the analysis population.	Up to 6 Months
Secondary	Duration of Response (CR, PR or marrow CR) for MDS patients	Duration of response will consist of only the subjects achieving a response (CR, PR or marrow CR) and is defined as the time from first observed response until either disease progression or any cause of death.	Up to 30 months
Secondary	Duration of Response (Clinical CR or Clinical PR) for JMML patients	Duration of response will consist of only the subjects achieving a response (cCR or cPR) and is defined as the time from first observed response until either disease progression or any cause of death.	Up to 18 months
Secondary	Time to Response (TTR) for MDS patients	TTR is defined as the time from first study dose day until a response of CR, PR or marrow CR, whichever occurs first. Only subjects observed with a response will be included in the analysis with the median TTR across the subjects presented.	Up to 6 Months
Secondary	TTR of Clinical CR or Clinical PR for JMML patients	Time to Response (TTR) is defined as the time from first study dose day until a response cCR or cPR, whichever occurs first. Only subjects observed with a response will be included in the analysis with the median TTR across the subjects presented.	Up to 6 Months
Secondary	Time to Progression (TTP)	Time to Progression (TTP) is defined as the time from first study dose day until either disease progression or death due to progression.	Up to 18 months
Secondary	Leukemia free survival (LFS)	Leukemia free survival (LFS) is defined as the time from HEMATOPOIETIC STEM CELL transplant (HSCT) date until leukemia progression or death for subjects receiving a HSCT only. Subjects alive and leukemia-free at the time of the statistical analysis will be censored at the time of their last disease assessment. Subjects will also be censored at the time of starting a new anticancer therapy if having not previously had a leukemia progression.	Up to 18 months
Secondary	Overall survival (OS)	OS is defined as the time from first study dose day until death from any cause. Subjects alive at the time of analysis will be censored at the time they were last known to be alive.	Up to 18 months
Secondary	Deoxyribonucleic acid methylation status in (BM)	DNA methylation levels will be assessed across time points by means of a repeated measures analysis of variance (ANOVA) test thereby allowing identification of possible changes in methylation levels over time by treatment arm as well as comparing DNA methylation levels between treatment arms per disease indication	Up to 18 months
Secondary	Percentage of subjects undergoing HSCT	Defined as the proportion of subjects undergoing HSCT during the conduct of this study over the total number of subjects enrolled into this study.	Up to 18 months
Secondary	Time to first HSCT	The time from first study dose day until HSCT date. Subjects not receiving a HSCT will be censored at the time of the analysis.	Up to 18 months
Secondary	Adverse Events (AEs)	All reported adverse events during the duration of the study conduct.	Up to 7 months
Secondary	Pharmacokinetic parameters of azacitidine; Cmax	Cmax is defined as the observed maximum plasma concentration	Up to 28 days
Secondary	Pharmacokinetic parameters of azacitidine; Tmax	Tmax is defined as the observed time to maximum plasma concentration	Up to 28 days
Secondary	Pharmacokinetic parameters of azacitidine; AUCt	Area under the plasma concentration-time curve from time zero to the last quantifiable time point	Up to 28 days
Secondary	Pharmacokinetic parameters of azacitidine; area under the plasma concentration-time curve from time zero to infinity (AUC 8)	The AUC 8 is defined as area under the plasma concentration-time curve from time zero to infinity	Up to 28 days
Secondary	Pharmacokinetic parameters of azacitidine; Terminal Rate ?z	Terminal phase rate constant is determined by linear regression of the terminal points of the log-linear plasma concentration-time curve	Up to 28 days
Secondary	Pharmacokinetic parameters of azacitidine; terminal phase half-life	The Terminal phase half-life will be calculated according to the following equation: t½ = 0.693/?z	Up to 28 days
Secondary	Pharmacokinetic parameters of azacitidine; total clearance (CL)	The total clearance is calculated as Dose/AUC8	Up to 28 days
Secondary	Pharmacokinetic parameters of azacitidine; volume of distribution (Vz)	The volume of distribution will be calculated according to the equation: Vz = (CL)/?z	Up to 28 days

External Links

•   Expanded Access for CC-486